This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2022 May;207(5):1019.

doi: 10.1097/JU.0000000000002425.01. Epub 2022 Feb 10.

Editorial Comment

Nicolas Sayegh¹, Umang Swami¹

Affiliations

PMID: 35143329
DOI: 10.1097/JU.0000000000002425.01

Editorial

Editorial Comment

Nicolas Sayegh et al. J Urol. 2022 May.

. 2022 May;207(5):1019.

doi: 10.1097/JU.0000000000002425.01. Epub 2022 Feb 10.

Authors

Nicolas Sayegh¹, Umang Swami¹

Affiliation

¹ Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.

PMID: 35143329
DOI: 10.1097/JU.0000000000002425.01

No abstract available

PubMed Disclaimer

Comment on

Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide.
Pan A, Reingold RE, Zhao JL, Moy A, Kraehenbuehl L, Dranitsaris G, McBride SM, Scher HI, Kollmeier MA, Xiao H, Rathkopf DE, Lacouture ME. Pan A, et al. J Urol. 2022 May;207(5):1010-1019. doi: 10.1097/JU.0000000000002425. Epub 2022 Jan 12. J Urol. 2022. PMID: 35020444 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources